UA43391C2 - Спосіб інгібування міжклітинного зчеплення і спосіб інгібування запального процесу та порушеного процесу нормальної коагуляції у пацієнтів з розладами васкулярного ендотелію - Google Patents
Спосіб інгібування міжклітинного зчеплення і спосіб інгібування запального процесу та порушеного процесу нормальної коагуляції у пацієнтів з розладами васкулярного ендотеліюInfo
- Publication number
- UA43391C2 UA43391C2 UA97084166A UA97084166A UA43391C2 UA 43391 C2 UA43391 C2 UA 43391C2 UA 97084166 A UA97084166 A UA 97084166A UA 97084166 A UA97084166 A UA 97084166A UA 43391 C2 UA43391 C2 UA 43391C2
- Authority
- UA
- Ukraine
- Prior art keywords
- inhibition
- disorders
- patients
- disrupted
- vascular endothelium
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pyrrole Compounds (AREA)
Abstract
Спосіб інгібування міжклітинного зчеплення включає введення людині, яка потребує цього, ефективної кількості хлористоводневої солі сполуки, яка має формулу де R1 та R3, незалежно, водень, або де Аr - факультативно заміщений феніл, R2 належить до групи, до складу якої входять піролідин, гексаметиленіміно та піперидино, або фармацевтично прийнятні солі або сольвати.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/385,934 US5484808A (en) | 1995-02-09 | 1995-02-09 | Methods of inhibiting cell-cell adhesion |
PCT/US1996/002657 WO1996024384A1 (en) | 1995-02-09 | 1996-02-09 | Methods of inhibiting cell-cell adhesion |
Publications (1)
Publication Number | Publication Date |
---|---|
UA43391C2 true UA43391C2 (uk) | 2001-12-17 |
Family
ID=23523494
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UA97084166A UA43391C2 (uk) | 1995-02-09 | 1996-02-09 | Спосіб інгібування міжклітинного зчеплення і спосіб інгібування запального процесу та порушеного процесу нормальної коагуляції у пацієнтів з розладами васкулярного ендотелію |
Country Status (17)
Country | Link |
---|---|
US (2) | US5484808A (uk) |
EP (1) | EP0726071A2 (uk) |
JP (1) | JPH10513475A (uk) |
KR (1) | KR19980702079A (uk) |
CN (1) | CN1072931C (uk) |
AU (1) | AU693021B2 (uk) |
CA (1) | CA2212339A1 (uk) |
CZ (1) | CZ286448B6 (uk) |
HU (1) | HUP9801323A3 (uk) |
IL (1) | IL117079A (uk) |
MY (1) | MY132251A (uk) |
NO (1) | NO973635L (uk) |
NZ (1) | NZ305072A (uk) |
RU (1) | RU2179021C2 (uk) |
UA (1) | UA43391C2 (uk) |
WO (1) | WO1996024384A1 (uk) |
ZA (1) | ZA961076B (uk) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6515009B1 (en) | 1991-09-27 | 2003-02-04 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5811447A (en) * | 1993-01-28 | 1998-09-22 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5770609A (en) | 1993-01-28 | 1998-06-23 | Neorx Corporation | Prevention and treatment of cardiovascular pathologies |
US6251920B1 (en) | 1993-05-13 | 2001-06-26 | Neorx Corporation | Prevention and treatment of cardiovascular pathologies |
US6491938B2 (en) | 1993-05-13 | 2002-12-10 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
WO1996040098A2 (en) | 1995-06-07 | 1996-12-19 | Neorx Corporation | Prevention and treatment of cardiovascular pathologies with tamoxifen analogues |
US20030083733A1 (en) * | 1997-10-10 | 2003-05-01 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5837313A (en) * | 1995-04-19 | 1998-11-17 | Schneider (Usa) Inc | Drug release stent coating process |
US6099562A (en) * | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
US20020091433A1 (en) * | 1995-04-19 | 2002-07-11 | Ni Ding | Drug release coated stent |
US5747509A (en) * | 1996-06-03 | 1998-05-05 | Schering Aktiengesellschaft | Method for lowering plasma levels of lipoprotein(a) |
US5773432A (en) * | 1996-10-30 | 1998-06-30 | Schering Aktiengesellschaft | Method for lowering plasma levels of lipoprotein(a) |
WO1998046588A2 (en) | 1997-04-11 | 1998-10-22 | Neorx Corporation | Compounds and therapies for the prevention of vascular and non-vascular pathologies |
US6008232A (en) * | 1997-08-20 | 1999-12-28 | Eli Lilly And Company | Methods for preventing headaches |
US6420391B1 (en) | 1998-04-01 | 2002-07-16 | Ono Pharmaceutical Co., Ltd. | Fused thiophone derivatives and drugs containing the same as the active ingredient |
EP1175433B1 (en) | 1999-05-04 | 2005-08-03 | Strakan International Limited | Androgen glycosides and androgenic activity thereof |
US6359015B1 (en) | 2000-02-28 | 2002-03-19 | The United States Of America As Represented By The Department Of Veterans Affairs | Method for antagonizing inhibition effects of alcohol on cell adhesion |
US20040121313A1 (en) | 2002-12-06 | 2004-06-24 | Ecker David J. | Methods for rapid detection and identification of bioagents in organs for transplantation |
US20030027135A1 (en) * | 2001-03-02 | 2003-02-06 | Ecker David J. | Method for rapid detection and identification of bioagents |
WO2004060278A2 (en) * | 2002-12-06 | 2004-07-22 | Isis Pharmaceuticals, Inc. | Methods for rapid identification of pathogens in humans and animals |
US7666588B2 (en) | 2001-03-02 | 2010-02-23 | Ibis Biosciences, Inc. | Methods for rapid forensic analysis of mitochondrial DNA and characterization of mitochondrial DNA heteroplasmy |
US6613083B2 (en) * | 2001-05-02 | 2003-09-02 | Eckhard Alt | Stent device and method |
JP3887588B2 (ja) * | 2002-08-30 | 2007-02-28 | 株式会社リガク | X線回折による応力測定法 |
US6977272B2 (en) * | 2002-10-16 | 2005-12-20 | President And Fellows Of Harvard College | Method for antagonizing inhibition effects of alcohol on cell adhesion |
US7964343B2 (en) * | 2003-05-13 | 2011-06-21 | Ibis Biosciences, Inc. | Method for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture |
US8097416B2 (en) | 2003-09-11 | 2012-01-17 | Ibis Biosciences, Inc. | Methods for identification of sepsis-causing bacteria |
US8546082B2 (en) | 2003-09-11 | 2013-10-01 | Ibis Biosciences, Inc. | Methods for identification of sepsis-causing bacteria |
US20120122102A1 (en) * | 2003-09-11 | 2012-05-17 | Rangarajan Sampath | Compositions for use in identification of bacteria |
US8163895B2 (en) | 2003-12-05 | 2012-04-24 | Ibis Biosciences, Inc. | Compositions for use in identification of orthopoxviruses |
US20050266411A1 (en) * | 2004-05-25 | 2005-12-01 | Hofstadler Steven A | Methods for rapid forensic analysis of mitochondrial DNA |
EP1904655A2 (en) * | 2005-07-21 | 2008-04-02 | Isis Pharmaceuticals, Inc. | Methods for rapid identification and quantitation of nucleic acid variants |
CN107412248A (zh) | 2016-05-24 | 2017-12-01 | 中国医学科学院药物研究所 | 三乙酰基-3-羟基苯基腺苷在治疗血管炎症或改善血管内皮功能中的应用 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4133814A (en) * | 1975-10-28 | 1979-01-09 | Eli Lilly And Company | 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents |
US4380635A (en) * | 1981-04-03 | 1983-04-19 | Eli Lilly And Company | Synthesis of acylated benzothiophenes |
US4418068A (en) * | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
US5395842A (en) * | 1988-10-31 | 1995-03-07 | Endorecherche Inc. | Anti-estrogenic compounds and compositions |
JP3157882B2 (ja) * | 1991-11-15 | 2001-04-16 | 帝国臓器製薬株式会社 | 新規なベンゾチオフエン誘導体 |
US5356926A (en) * | 1992-02-24 | 1994-10-18 | Warner-Lambert Company | 3-alkyloxy-, aryloxy-, or arylalkyloxy-benzo [β]thiophene-2-carboxamides as inhibitors of cell adhesion |
TW383306B (en) * | 1992-12-22 | 2000-03-01 | Lilly Co Eli | New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol |
US5457113A (en) * | 1993-10-15 | 1995-10-10 | Eli Lilly And Company | Methods for inhibiting vascular smooth muscle cell proliferation and restinosis |
UA32427C2 (uk) * | 1993-10-15 | 2000-12-15 | Елі Ліллі Енд Компані | Застосування бензотіофенів або їх фармацевтично прийнятних солей або сольватів для інгібування ангіогенезу і/або ангіогенних захворювань |
US5441965A (en) * | 1993-12-21 | 1995-08-15 | Eli Lilly And Company | Methods of inhibiting thrombin |
US5574047A (en) * | 1993-12-21 | 1996-11-12 | Eli Lilly And Company | Methods of inhibiting imperfect tissue repair |
US5476862A (en) * | 1993-12-21 | 1995-12-19 | Eli Lilly And Company | Methods of increasing thrombomodulin expression |
-
1995
- 1995-02-09 US US08/385,934 patent/US5484808A/en not_active Expired - Fee Related
- 1995-04-14 US US08/422,295 patent/US5496851A/en not_active Expired - Fee Related
-
1996
- 1996-02-08 IL IL11707996A patent/IL117079A/xx not_active IP Right Cessation
- 1996-02-09 NZ NZ305072A patent/NZ305072A/en unknown
- 1996-02-09 KR KR1019970705474A patent/KR19980702079A/ko not_active Application Discontinuation
- 1996-02-09 CA CA002212339A patent/CA2212339A1/en not_active Abandoned
- 1996-02-09 WO PCT/US1996/002657 patent/WO1996024384A1/en not_active Application Discontinuation
- 1996-02-09 CN CN96191839A patent/CN1072931C/zh not_active Expired - Fee Related
- 1996-02-09 MY MYPI96000491A patent/MY132251A/en unknown
- 1996-02-09 JP JP8524495A patent/JPH10513475A/ja not_active Withdrawn
- 1996-02-09 UA UA97084166A patent/UA43391C2/uk unknown
- 1996-02-09 HU HU9801323A patent/HUP9801323A3/hu unknown
- 1996-02-09 RU RU97114956/14A patent/RU2179021C2/ru active
- 1996-02-09 ZA ZA9601076A patent/ZA961076B/xx unknown
- 1996-02-09 AU AU52996/96A patent/AU693021B2/en not_active Ceased
- 1996-02-09 CZ CZ19972482A patent/CZ286448B6/cs not_active IP Right Cessation
- 1996-02-09 EP EP96300876A patent/EP0726071A2/en not_active Withdrawn
-
1997
- 1997-08-06 NO NO973635A patent/NO973635L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
IL117079A0 (en) | 1996-06-18 |
CA2212339A1 (en) | 1996-08-15 |
EP0726071A3 (uk) | 1996-09-11 |
MY132251A (en) | 2007-09-28 |
WO1996024384A1 (en) | 1996-08-15 |
CN1072931C (zh) | 2001-10-17 |
HUP9801323A3 (en) | 1999-09-28 |
IL117079A (en) | 1999-12-31 |
CZ248297A3 (cs) | 1998-06-17 |
RU2179021C2 (ru) | 2002-02-10 |
CN1173821A (zh) | 1998-02-18 |
NZ305072A (en) | 2000-07-28 |
US5484808A (en) | 1996-01-16 |
US5496851A (en) | 1996-03-05 |
AU5299696A (en) | 1996-08-27 |
ZA961076B (en) | 1997-08-11 |
AU693021B2 (en) | 1998-06-18 |
KR19980702079A (ko) | 1998-07-15 |
EP0726071A2 (en) | 1996-08-14 |
NO973635D0 (no) | 1997-08-06 |
MX9706072A (es) | 1997-10-31 |
JPH10513475A (ja) | 1998-12-22 |
NO973635L (no) | 1997-09-29 |
HUP9801323A2 (hu) | 1999-05-28 |
CZ286448B6 (en) | 2000-04-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA43391C2 (uk) | Спосіб інгібування міжклітинного зчеплення і спосіб інгібування запального процесу та порушеного процесу нормальної коагуляції у пацієнтів з розладами васкулярного ендотелію | |
AU8155894A (en) | Methods of inhibiting thrombin | |
MY132056A (en) | Methods of inhibiting physiological conditions associated with an excess of neuropeptide y. | |
MX9701329A (es) | Metodos para la inhibicion de la replicacion viral. | |
PT651999E (pt) | Metodos de inibicao da fibrose uterina | |
MX9701360A (es) | Metodos para la inhibicion de la desmielinizacion y las enfermedades de la dismielinizacion. | |
MY112973A (en) | Methods for inhibiting vascular smooth muscle cell migration | |
UA27910C2 (uk) | Засіб для підвищення експресії тромбомодуліну та підвищення активації протеїну с | |
MX9709466A (es) | Medicamento para inhibir el melanoma. | |
MY113406A (en) | Methods of inhibiting physiological conditions associated with an excess of bradykinin | |
MX9701333A (es) | Metodos para inhibir el daño neuronal. | |
AU8155094A (en) | Methods of inhibiting hirsutism and alopecia in women | |
MX9702148A (es) | Metodos para inhibir la mitosis endometrial. | |
MX9701327A (es) | Metodos para inhibir el cancer endometrial. | |
MX9701331A (es) | Metodos para mantener los dientes y los huesos bucales. | |
MX9701359A (es) | Metodos para la inhibicion de la hiperplasia endometrial primaria. | |
MX9709536A (es) | Metodo para reducir el factor de transcripcion bef-1. | |
MX9701328A (es) | Metodos de reduccion de la cicatrizacion en la curacion de heridas. | |
MX9705215A (es) | Uso de 2-fenil-3-aroilbenzotiofenos para inhibir los efectos de la hormona del crecimiento. | |
MX9709651A (es) | Metodos para modulacion del factor de transcripcion nf-kb. | |
MX9705940A (es) | Metodos y composiciones para inhibir los efectos de la interleucina 6. | |
MX9706520A (es) | Metodos para inhibir el cancer de ovario. | |
MX9705697A (es) | Metodos para reducir los niveles de calcio del suero. | |
MX9705537A (es) | Metodos y composiciones para inhibir el efecto de los estrogenos del medio ambiente. |